Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€6.50

€6.50

-2.070%
-0.134
-2.070%
€13.70
 
19.04.24 / Tradegate WKN: A2N5Z6 / Symbol: ALT / Name: Altimmune / Stock / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Altimmune Stock

A loss of -2.070% shows a downward development for Altimmune.
We see a rather positive sentiment for Altimmune with 8 Buy predictions and 1 Sell predictions.
With a target price of 13 € there is potential for a 100.15% increase which would mean more than doubling the current price of 6.5 € for Altimmune.
Our community identified positive and negative aspects for Altimmune stock for the coming years. 7 users see the criterium "Worthwhile Investment for the next years" as a plus for the Altimmune stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.

Pros and Cons of Altimmune in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-25

Upon first glance, the financials of Altimmune, Inc. (ALT) seem to present a mixed picture. The company has managed to maintain a relatively stable asset base over the past few years, but a consistent net loss in its income statements indicates ongoing challenges in operational efficiency. In order to provide a more comprehensive evaluation, this article will delve into the pros and cons of the company's financial performance.

Stable Total Assets: A closer look at the balance sheets reveals that Altimmune's total assets have remained relatively consistent throughout the years, with USD 206.9 million in 2022, USD 218.9 million in 2021, and USD 245.1 million in 2020. This stability suggests that the company is maintaining its asset base and could indicate financial stability.

High Net Working Capital: ALT's net working capital is quite strong, showing a surplus of resources to meet short-term obligations. In 2022, their net working capital was USD 175.8 million, indicating a healthy liquidity position.

Comments

Prediction Buy
Perf. (%) -38.14%
Target price 11.170
Change
Ends at 01.04.25

Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -32.41%
Target price 18.508
Change
Ends at 28.03.25

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 85.57%
Target price 13.770
Change
Ends at 01.12.24

Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Show more

News

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?: https://www.marketbeat.com/logos/articles/med_20240408193046_can-altimmune-get-its-glp-1-drug-to-market-before.jpg
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biotechnology company specializing in treating liver disease and obesity. Their lead drug, Pemvidutide, has garnered much attention as a

Can Altimmune's weight-loss drug be a game-changer?: https://www.marketbeat.com/logos/articles/med_20231210135443_chart-alt.jpg
Can Altimmune's weight-loss drug be a game-changer?

The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold rush for new weight-loss drugs in the medical